ArticlePreventive medicine reports2025
Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study.Alimentary pharmacology & therapeutics · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut and liver · 2026Review
- Portal hypertension mortality in the United States (1999-2023): Insights from the CDC WONDER database.Medicine · 2026Article
- Factors influencing self-management behaviors in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.Preventive medicine reports · 2026Review
- Upregulation of T-type voltage-dependent Ca²⁺ channels in activated hepatic stellate cells promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.Pflugers Archiv : European journal of physiology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study.Cancers · 2026Article
- Asia at the Epicenter of the Global Cardiometabolic Shift.JACC. Asia · 2026Review
- Cannabidiol-Ion Channel Interactions Represent a Promising Preventive and Therapeutic Strategy in Hepatocellular Carcinoma.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- A Retrospective Analysis of Hepatic Disease Burden and Progression in a Hospital-Based Romanian Cohort Using Integrated Cross-Sectional and Longitudinal Data (2019-2023).Journal of clinical medicine · 2026Article
- Association between the subcellular localization of host proteins and gut microbiome and metabolome in metabolic dysfunction-associated steatotic liver disease: a pilot study.Frontiers in molecular biosciences · 2026Article
- Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction-Associated Steatotic Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Although the update of the MASLD practice guidelines and the approval of Resmetirom have brought new progress in the prevention and treatment of MASLD, this disease still has not received sufficient attention and remains a major public health issue. Methods: Age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and disability-adjusted life years (ASDR) rates of MASLD from 1990 to 2021 were extracted from the Global Burden of Disease 2021. The estimated annual percentage change was calculated using linear regression. Six time-series models were used for training and comparison, and the optimal model was selected to predict the disease burden from 2022 to 2031. Results: Globally, the ASIR, ASPR, ASMR, and ASDR all exhibited upward trends. Regionally, Western Europe showed the fastest growth in ASIR and ASPR. Eastern Europe showed the fastest growth in ASMR and ASDR, whereas the high-income Asia Pacific demonstrated the most pronounced decline. The hybrid model best predicted ASIR (615.70/100,000) and ASPR (15,275.60/100,000) for 2031, the Neural Network Autoregressive model optimized ASMR (1.64/100,000), and Prophet projected ASDR to decline to 42.08/100,000. Conclusions: The MASLD burden has increased globally and is projected to continue escalating. It is suggested that the MASLD screening be integrated into the non-communicable diseases program and be prioritized for monitoring in high-burden areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.